Скачать с ютуб Update on ALLELE: tab-cel in patients with EBV+ PTLD following alloSCT after rituximab failure в хорошем качестве

Update on ALLELE: tab-cel in patients with EBV+ PTLD following alloSCT after rituximab failure

Amer Beitinjaneh, MD, University of Miami, Jackson Memorial Hospital, Miami, FL, shares the updated results of the Phase III ALLELE study (NCT03394365) of tabelecleucel (tab-cel) for patients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD) following allogeneic stem cell transplant (alloSCT) or solid organ transplant after rituximab failure. Prof. Beitinjaneh describes the characteristics of the patients included in this study and outlines the findings from the study, which indicated that tab-cel leads to high and durable responses. In addition, overall survival (OS) was higher in responders versus non-responders, and there were no safety concerns associated with tab-cel treatment. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.